Synthetic-Polymer-Based Cardiac Patches for MI-Induced Heart Failure Treatment: A Review

Ahmed Eliwa1,2, Mohamed K Abbas3, Maryam Al-Ejji3

  • 1College of Medicine, Qatar University, Doha P.O. Box 2713, Qatar.

Biomolecules
|May 4, 2026
PubMed

Insights

Synthetic polymer cardiac patches offer a promising treatment for heart failure following myocardial infarction (MI). These advanced scaffolds improve cardiac function and provide mechanical support, addressing critical needs in cardiovascular disease therapy.

Area of Science:

  • Biomedical Engineering
  • Materials Science
  • Cardiovascular Research

Background:

  • Myocardial infarction (MI) leads to heart failure due to cardiac tissue damage.
  • Cardiac patches are polymer scaffolds designed to repair heart tissue and improve function.
  • Current research focuses on synthetic polymers for advanced cardiac patch fabrication.

Purpose of the Study:

  • To review recent advancements in synthetic-polymer-based cardiac patches for treating MI-induced heart failure.
  • To analyze the mechanical and chemical properties of various synthetic polymers used in cardiac patches.
  • To outline challenges and future directions in cardiac patch technology.

Main Methods:

  • Literature review of synthetic polymer cardiac patches for myocardial infarction.
  • Analysis of mechanical and chemical characteristics of different synthetic polymers.
  • Discussion of benefits, drawbacks, challenges, and future prospects.

Main Results:

  • Synthetic polymer cardiac patches demonstrate significant therapeutic effects in preclinical models.
  • Specific polymers offer distinct advantages in terms of mechanical support and bioactive substance delivery.
  • Key challenges include long-term stability, integration with host tissue, and scalable manufacturing.

Conclusions:

  • Synthetic polymer cardiac patches represent a viable strategy for mitigating heart failure post-MI.
  • Tailoring polymer properties is crucial for optimizing patch performance and patient outcomes.
  • Continued innovation is needed to overcome current limitations and advance clinical translation.

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
343
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805